Targeted Delivery of CNS Therapeutics
To achieve safe and effective doses of gene therapy in CNS targets (typically10¹⁰-10¹² vg/cm³), slow and controlled infusions through several micro-cannulas are required. The Neurochase drug delivery system has been designed to facilitate the accurate insertion of multiple flexible cannulas to brain targets in a short theatre time. Surgeries are pre-planned, and the tooling and workflow make the procedure simple and not dependent on individual surgeon’s technical ability (“brainless brain surgery”). Simultaneous cannula infusions can then be conducted safely in awake patients with neurological and MRI monitoring. The micro catheters are removed under local anaesthetic. We believe that our technology provides a truly scalable solution to treating neurological diseases with the direct delivery of gene and other therapies to the CNS.
Convection Enhanced Delivery
CED provides a method of achieving effective doses of therapeutics homogenously in targeted brain volumes that cannot be achieved safely with systemic or CSF delivery. Therapies are infused into the brain via micro-catheters and can be distributed in tightly controlled doses throughout the required treatment volume. The blood brain barrier now acts to retain the therapy in the brain targets thereby minimising systemic and off-target exposure. We believe that safe and scalable delivery of novel therapeutics by CED is achievable and will transform human health by unlocking treatments to previously untreatable neurological disorders.
Neurochase was founded by a team of physician-scientists led by Professor Steven Gill in response to the growing need for CED consultancy services in the life science industry. Professor Gill is an Honorary Professor of Neurosurgery at the University of Bristol. He is a world leading expert in CED and has spent the past 20 years developing technology to facilitate highly accurate and safe targeting of deep brain structures using software and surgical robots. To learn more about Professor Gill, watch the following video interview where he discusses his clinical experience of intermittently delivering chemotherapy directly to paediatric brainstem tumours using his novel implantable neurosurgical device.
Neurosurgical Infusion Consultation & Analysis
GLP & Non-GLP Studies
Study Design and Protocol Generation
May 12, 2022
"AviadoBio, a pioneering, pre-clinical stage, gene therapy company focused on developing and delivering transformative medicines for people with neurodegenerative disorders, announces that it has established a Scientific Advisory Board (SAB) comprising world-leading experts in neurodegenerative diseases, neurosurgical drug delivery and gene therapy development..."
June 14, 2022
"Today, Hamlet Pharma signed a joint development agreement with Neurochase Limited, founded by Professor Steven Gill, a world leading expert in the area of neurosurgery, to develop novel technology and methods to treat Central Nervous System (CNS) tumors with Alpha1H...."
February 8, 2022
"CombiGene announced that the company, together with its partner Neurochase, had started the work to optimize the administration of CG01 in a preclinical pilot study in a large animal model..."
January 25, 2022
"Innervate Therapeutics is a biotechnology company focused on developing glial cell -derived neurotrophic factor (GDNF) gene therapies to achieve neuro-restoration and neuroprotection in diseases including PD and MND...."
January 20, 2022
". In this case study, we present OXGENE’s work with Innervate Therapeutics, who are developing gene therapies for Parkinson’s and Motor Neuron Disease, that will be delivered directly to the brain via convection-enhanced delivery (CED)..."